New Ray Medicine International Holding Limited

SEHK:6108 Stock Report

Market Cap: HK$71.9m

New Ray Medicine International Holding Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Qiuqin Wang

Chief executive officer

HK$1.2m

Total compensation

CEO salary percentage17.7%
CEO tenure4.4yrs
CEO ownershipn/a
Management average tenure2.6yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

Lacklustre Performance Is Driving New Ray Medicine International Holding Limited's (HKG:6108) 34% Price Drop

Jan 26
Lacklustre Performance Is Driving New Ray Medicine International Holding Limited's (HKG:6108) 34% Price Drop

There's Reason For Concern Over New Ray Medicine International Holding Limited's (HKG:6108) Price

Jun 08
There's Reason For Concern Over New Ray Medicine International Holding Limited's (HKG:6108) Price

We're Keeping An Eye On New Ray Medicine International Holding's (HKG:6108) Cash Burn Rate

Mar 29
We're Keeping An Eye On New Ray Medicine International Holding's (HKG:6108) Cash Burn Rate

CEO Compensation Analysis

How has Qiuqin Wang's remuneration changed compared to New Ray Medicine International Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-HK$13m

Mar 31 2024n/an/a

-HK$18m

Dec 31 2023HK$1mHK$211k

-HK$22m

Sep 30 2023n/an/a

-HK$46m

Jun 30 2023n/an/a

-HK$70m

Mar 31 2023n/an/a

-HK$74m

Dec 31 2022HK$2mHK$222k

-HK$78m

Sep 30 2022n/an/a

-HK$52m

Jun 30 2022n/an/a

-HK$25m

Mar 31 2022n/an/a

-HK$14m

Dec 31 2021HK$1mHK$220k

-HK$3m

Sep 30 2021n/an/a

-HK$17m

Jun 30 2021n/an/a

-HK$32m

Mar 31 2021n/an/a

-HK$51m

Dec 31 2020HK$1mHK$174k

-HK$70m

Sep 30 2020n/an/a

-HK$71m

Jun 30 2020n/an/a

-HK$73m

Mar 31 2020n/an/a

-HK$58m

Dec 31 2019HK$874kHK$198k

-HK$44m

Sep 30 2019n/an/a

-HK$16m

Jun 30 2019n/an/a

HK$11m

Mar 31 2019n/an/a

HK$22m

Dec 31 2018HK$310kHK$122k

HK$33m

Compensation vs Market: Qiuqin's total compensation ($USD153.46K) is below average for companies of similar size in the Hong Kong market ($USD230.88K).

Compensation vs Earnings: Qiuqin's compensation has been consistent with company performance over the past year.

CEO

Qiuqin Wang (46 yo)

4.4yrs

Tenure

HK$1,192,000

Compensation

Ms. Qiuqin Wang serves as Executive Director at New Ray Medicine International Holding Limited since June 27, 2018 and serves as its Chief Executive Officer since July 31, 2020 and serves as its Chairman s...

Leadership Team

NamePositionTenureCompensationOwnership
Qiuqin Wang
CEO & Chairman4.4yrsHK$1.19mno data
Xueping Chu
Executive Director3.5yrsHK$360.00kno data
Wan Zhou
Executive Director1.8yrsHK$448.00kno data
Yat Sing Ng
Financial Controller & Company Secretary1.4yrsno datano data

2.6yrs

Average Tenure

41yo

Average Age

Experienced Management: 6108's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Qiuqin Wang
CEO & Chairman6.5yrsHK$1.19mno data
Xueping Chu
Executive Director3.5yrsHK$360.00kno data
Wan Zhou
Executive Director1.8yrsHK$448.00kno data
Lai Yin Sy
Independent Non-Executive Director6.3yrsHK$240.00kno data
Chi Kin Leung
Independent Non Executive Director11.3yrsHK$240.00kno data
Sin Ming Li
Independent Non-Executive Director7.5yrsHK$240.00kno data

6.4yrs

Average Tenure

47yo

Average Age

Experienced Board: 6108's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:38
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

New Ray Medicine International Holding Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai Ho LeeSBI China Capital Financial Services Limited